Logo

HYPR

Hyperfine, Inc.

HYPR

Hyperfine, Inc. • NASDAQ
$1.07 ▲ 2.88% (+0.03)
Market Cap $81.53 M
52w High $2.22
52w Low $0.53
Dividend Yield 0%
P/E -2.06
Volume 62.64K
Outstanding Shares 76.19M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $3.437M ▲ $10.768M ▼ $-11.019M ▼ -320.599% ▲ $-0.14 ▼ $-10.722M ▼
Q2-2025 $2.696M ▲ $10.923M ▼ $-9.225M ▲ -342.174% ▲ $-0.12 $-8.942M ▲
Q1-2025 $2.137M ▼ $11.785M ▲ $-9.418M ▲ -440.711% ▲ $-0.12 ▲ $-10.673M ▼
Q4-2024 $2.321M ▼ $11.591M ▼ $-10.39M ▼ -447.652% ▼ $-0.14 $-10.531M ▲
Q3-2024 $3.643M $12.871M $-10.326M -283.448% $-0.14 $-10.704M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $21.564M ▼ $41.511M ▼ $14.639M ▲ $26.872M ▼
Q2-2025 $25.42M ▼ $45.234M ▼ $10.108M ▼ $35.126M ▼
Q1-2025 $33.093M ▼ $53.377M ▼ $10.263M ▲ $43.114M ▼
Q4-2024 $37.645M ▼ $58.901M ▼ $9.861M ▼ $49.04M ▼
Q3-2024 $45.765M $69.386M $11.064M $58.322M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-11.019M ▼ $-5.582M ▲ $-130K ▲ $2.164M ▲ $-3.548M ▲ $-5.712M ▲
Q2-2025 $-9.225M ▲ $-7.91M ▲ $-520K ▼ $474K ▼ $-7.956M ▼ $-8.43M ▲
Q1-2025 $-9.418M ▲ $-9.249M ▼ $-472K ▼ $5.582M ▲ $-4.139M ▲ $-9.721M ▼
Q4-2024 $-10.39M ▼ $-8.357M ▲ $-8K ▲ $54K ▼ $-8.311M ▼ $-8.365M ▲
Q3-2024 $-10.326M $-8.517M $-159K $851K $-7.825M $-8.676M

Revenue by Products

Product Q4-2024Q1-2025Q2-2025Q3-2025
Product
Product
 $0 ▲$0 ▲$0 ▲$0 ▲
Service
Service
 $0 ▲$0 ▲$0 ▲$0 ▲

Five-Year Company Overview

Income Statement

Income Statement Hyperfine looks like a classic early‑stage med‑tech company: very small sales so far, but steadily improving losses. Revenue has only inched up and is still tiny compared with operating costs, which means the business is still in the commercialization and market‑education phase rather than true scale. On the positive side, losses have been trending lower over the last couple of years, suggesting some cost discipline and better gross margins as they gain experience and refine pricing. Still, the income statement clearly shows a company investing heavily ahead of revenue, not one that is yet close to profitability.

Balance Sheet

Balance Sheet The balance sheet is lean and dominated by cash, with little in the way of hard assets and no financial debt. Cash and total assets have come down meaningfully since the post‑SPAC period, reflecting ongoing funding of losses. Shareholders’ equity has also declined but remains positive, which is typical for a young company that has been spending its equity capital to build technology and commercial infrastructure. In simple terms, the balance sheet is clean but getting lighter, and the company’s future flexibility will depend on how long its remaining cash covers its current pace of spending.

Cash Flow

Cash Flow Cash flows underline the early‑stage profile. The company has been consistently burning cash from operations each year, and because capital spending is minimal, operating outflows and free cash outflows are effectively the same thing. This suggests a very asset‑light model where most money goes to people, R&D, and commercialization rather than factories or heavy equipment. While the rate of cash burn has improved somewhat, the business is still clearly cash‑consuming, meaning that sustained progress in sales or access to new capital will be important over time.

Competitive Edge

Competitive Edge Hyperfine occupies a distinct niche in medical imaging with its portable, low‑field MRI system focused on point‑of‑care neuroimaging. Its advantages include being a first mover with FDA‑cleared portable MRI, a sizeable patent and licensing portfolio, and a tightly integrated AI software layer that improves image quality and usability. These create meaningful barriers for new entrants. At the same time, the company is small and operates in a field dominated by large imaging players with deep resources. The market for portable MRI is still being shaped, so Hyperfine benefits from an early lead but faces the challenge of proving the value of this new category and defending it if bigger competitors decide to follow.

Innovation and R&D

Innovation and R&D Innovation is the core of Hyperfine’s strategy. The company’s key product combines novel low‑field magnet design with AI‑driven software, and management has signaled an aggressive roadmap, including next‑generation hardware and regular new product or feature releases. The AI stack is particularly important, as each new version can enhance the performance of the existing hardware and deepen the data and know‑how advantage. Partnerships, like work in lower‑income regions, point to broader, longer‑term use cases. The upside is a strong innovation engine and expanding moat; the risk is execution—maintaining rapid R&D progress, earning new regulatory clearances, and turning that pipeline into commercial traction without overextending resources.

Summary

Hyperfine is an early‑stage, high‑innovation medical device company trying to reshape MRI by making it portable and more accessible. Financially, it is still in the build‑out phase: revenue is modest, losses are ongoing but improving, and cash is being drawn down to fund operations rather than capital projects. The balance sheet is simple and debt‑free but increasingly reliant on careful cash management or future financing. Strategically, the company has a clear technological edge, a strong patent position, and a differentiated product supported by AI—factors that give it a credible competitive moat in a niche that large incumbents have not fully targeted. The main questions ahead are commercial: how quickly hospitals and clinics adopt portable MRI, how effectively Hyperfine scales its sales and support model, and whether it can align its cash runway with the time needed to turn its technological lead into a durable, self‑funding business.

NEWS

November 20, 2025 · 4:05 PM UTC

Hyperfine, Inc. to Participate in Upcoming Piper Sandler 37th Annual Healthcare Conference

Read more

November 19, 2025 · 8:15 AM UTC

Hyperfine Awarded $3.7 Million Grant to Advance Global Brain Health

Read more

November 13, 2025 · 4:05 PM UTC

Hyperfine, Inc. Reports Third Quarter 2025 Financial Results

Read more

October 21, 2025 · 8:15 AM UTC

Hyperfine Announces First Patients Enrolled in PRISM PMR to Evaluate the Use of Next-Generation Swoop® System in the Operating Room Setting

Read more

October 16, 2025 · 8:00 AM UTC

Hyperfine Announces Pricing of $17.5 Million Public Offering

Read more